Citations

Clear

299 citation(s) found for "Solomon, B".

Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk
Yuan, Fangcheng , Hung, Rayjean J. , Walsh, Naomi , Wheeler, William , Song, Lei , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Scélo, Ghislaine , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Fuchs, Charles S. , Gaziano, J. Michael , Hackert, Thilo , Hartge, Patricia, Hassan, Manal M. , Holly, Elizabeth A. , Hoover, Robert N. , Kirsten, Holger , Kurtz, Robert C. , Lee, I‐Min , Murphy, Neil , Ng, Kimmie , Oberg, Ann L. , Porta, Miquel , Rabe, Kari G. , Real, Francisco X. , Rothman, Nathaniel , Sesso, Howard D. , Thompson, Ian M. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Shi, Jianxin , Li, Donghui , Petersen, Gloria M. , Wolpin, Brian M. , Platz, Elizabeth A. , Arslan, Alan A , Canzian, Federico , Giles, Graham G , Bamlet, William R , Brennan, Paul , Hackert, Thilo , Katzke, Verena , Kirsten, Holger , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Wactawski-Wende, Jean , Yu, Herbert , Duell, Eric J , Amundadottir, Laufey , Li, Donghui , Klein, Alison P , Stolzenberg-Solomon, Rachael , Chaffee, Kari G. , Hung, Rayjean J , Visvanathan, Kala , Yuan, Fangcheng , Murphy, Neil , Porta, Miquel , Real, Francisco X , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Zhang, Han , Freeman, Laura E. Beane , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Rosendahl, Jonas , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Amiano, Pilar , Bamlet, William R. , Campbell, Peter T. , Chanock, Stephen Jacob , Goggins, Michael , Malats, Núria , Milne, Roger L. , Silverman, Debra T. , Wang, Xiaoliang , Wilkens, Lynne R. , Yu, Kai , Duell, Eric J. , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Research | July 8, 2020 | Volume: 80 | Issue: 18 | Pages: 4004-4013

10.1158/0008-5472.can-20-0447 | PMID 32641412 Get It

Abstract Registry-based epidemiologic studies suggest associations between chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). As genetic susceptibility contributes to a large proportion of chronic inflammatory intestinal diseases, we hypothesize that the genomic regions surrounding established genome-wide associated variants for these chronic inflammatory diseases are associated with PDAC. We examined the association between PDAC and genomic regions (±500 kb) surrounding established common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis. We analyzed summary statistics from genome-wide association studies data for 8,384 cases and 11,955 controls of European descent from two large consortium studies using the summary data-based adaptive rank truncated product method to examine the overall association of combined genomic regions for each inflammatory disease group. Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated with PDAC at P values < 0.05 (0.0040, 0.0057, 0.011, and 3.4 × 10−6, respectively). After excluding the 20 PDAC susceptibility regions (±500 kb) previously identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P = 0.0029, 0.0057, and 0.0098, respectively). Genomic regions for celiac disease (P = 0.22) and primary sclerosing cholangitis (P = 0.078) were not associated with PDAC. Our results support the hypothesis that genomic regions surrounding variants associated with inflammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated with PDAC. Significance: The joint effects of common variants in genomic regions containing susceptibility loci for inflammatory bowel disease and chronic pancreatitis are associated with PDAC and may provide insights to understanding pancreatic cancer etiology.
Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis
Wagner, Tyler , Shweta, Fnu , Awasthi, Samir , Bade, Sairam, Puranik, Arjun, Kang, Martin , Pickering, Brian W. , O’Horo, John C. , Vergidis, Paschalis , Temesgen, Zelalem , Rizza, Stacey A. , Mahmood, Maryam , Wilson, Walter R. , Liebers, Matt, Doctor, Zainab M., Silvert, Eli , Solomon, Hugo, Barve, Rakesh , Williams, Amy W. , Morice, William G. , Badley, Andrew D. , Venkatakrishnan, A J , O'Horo, John C, Rizza, Stacey , Challener, Douglas , Anand, Praveen , Badley, Andrew, Soundararajan, Venky , Badley, Andrew D , O'Horo, John C , Vergidis, Paschalis , Mahmood, Maryam , Shweta, Fnu , Wagner, Tyler, Murugadoss, Karthik , Bauer, Philippe R. , Razonable, Raymund R. , Challener, Douglas W. , Anand, Praveen , Anand, Akash, Gores, Gregory J. , Morice, William George , Halamka, John , Soundararajan, Venky

Mayo Clinic

eLife | July 7, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.58227 | PMID 32633720 Get It

Understanding temporal dynamics of COVID-19 symptoms could provide fine-grained resolution to guide clinical decision-making. Here, we use deep neural networks over an institution-wide platform for the augmented curation of clinical notes from 77,167 patients subjected to COVID-19 PCR testing. By contrasting Electronic Health Record (EHR)-derived symptoms of COVID-19-positive (COVID pos ; n = 2,317) versus COVID-19-negative (COVID neg ; n = 74,850) patients for the week preceding the PCR testing date, we identify anosmia/dysgeusia (27.1-fold), fever/chills (2.6-fold), respiratory difficulty (2.2-fold), cough (2.2-fold), myalgia/arthralgia (2-fold), and diarrhea (1.4-fold) as significantly amplified in COVID pos over COVID neg patients. The combination of cough and fever/chills has 4.2-fold amplification in COVID pos patients during the week prior to PCR testing, in addition to anosmia/dysgeusia, constitutes the earliest EHR-derived signature of COVID-19. This study introduces an Augmented Intelligence platform for the real-time synthesis of institutional biomedical knowledge. The platform holds tremendous potential for scaling up curation throughput, thus enabling EHR-powered early disease diagnosis.
Genome-Wide Gene–Diabetes and Gene–Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia
Tang, Hongwei, Jiang, Lai , Arslan, Alan A. , Bracci, Paige M. , Brennan, Paul , Canzian, Federico , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Campa, Daniele , Childs, Erica J., Fuchs, Charles S. , Gaziano, J. Michael , Hartge, Patricia, Hassam, Manal H., Holly, Elizabeth A. , Hoover, Robert N. , Hung, Rayjean J. , Kurtz, Robert C. , Lee, I-Min, Ng, Kimmie , Oberg, Ann L. , Peters, Ulrike , Porta, Miquel , Rabe, Kari G. , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Thompson, Ian M. , Tjønneland, Anne , Trichopoulou, Antonia , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Chatterjee, Nilanjan , Li, Donghui , Arslan, Alan A , Brennan, Paul , Canzian, Federico , Bamlet, William R , Blackford, Amanda , Duell, Eric J , Hung, Rayjean J , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Orlow, Irene , Sesso, Howard D , Tjønneland, Anne , Wactawski-Wende, Jean , Yu, Herbert , Amundadottir, Laufey , Klein, Alison P , Li, Donghui , Chaffee, Kari G. , Visvanathan, Kala , Porta, Miquel , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Stolzenberg‐Solomon, Rachael Z. , Freeman, Laura E. Beane , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Chanock, Stephen Jacob , Duell, Eric J. , Goggins, Michael , Malats, Núria , Milne, Roger L. , Orlow, Irene , Rothman, Nathaniel , Silverman, Debra T. , Wilkens, Lynne R. , Yu, Kai , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Kraft, Peter , Wei, Peng

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 16, 2020 | Volume: 29 | Issue: 9 | Pages: 1784-1791

10.1158/1055-9965.epi-20-0275 | PMID 32546605 Get It

Abstract Background: Obesity and diabetes are major modifiable risk factors for pancreatic cancer. Interactions between genetic variants and diabetes/obesity have not previously been comprehensively investigated in pancreatic cancer at the genome-wide level. Methods: We conducted a gene–environment interaction (GxE) analysis including 8,255 cases and 11,900 controls from four pancreatic cancer genome-wide association study (GWAS) datasets (Pancreatic Cancer Cohort Consortium I–III and Pancreatic Cancer Case Control Consortium). Obesity (body mass index ≥30 kg/m2) and diabetes (duration ≥3 years) were the environmental variables of interest. Approximately 870,000 SNPs (minor allele frequency ≥0.005, genotyped in at least one dataset) were analyzed. Case–control (CC), case-only (CO), and joint-effect test methods were used for SNP-level GxE analysis. As a complementary approach, gene-based GxE analysis was also performed. Age, sex, study site, and principal components accounting for population substructure were included as covariates. Meta-analysis was applied to combine individual GWAS summary statistics. Results: No genome-wide significant interactions (departures from a log-additive odds model) with diabetes or obesity were detected at the SNP level by the CC or CO approaches. The joint-effect test detected numerous genome-wide significant GxE signals in the GWAS main effects top hit regions, but the significance diminished after adjusting for the GWAS top hits. In the gene-based analysis, a significant interaction of diabetes with variants in the FAM63A (family with sequence similarity 63 member A) gene (significance threshold P < 1.25 × 10−6) was observed in the meta-analysis (PGxE = 1.2 ×10−6, PJoint = 4.2 ×10−7). Conclusions: This analysis did not find significant GxE interactions at the SNP level but found one significant interaction with diabetes at the gene level. A larger sample size might unveil additional genetic factors via GxE scans. Impact: This study may contribute to discovering the mechanism of diabetes-associated pancreatic cancer.
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
Shah, Manisha H. , Sherman, Eric J. , Lorch, Jochen H. , Brose, Marcia S. , Godbert, Yann , Meurer, Marie, Tan, Daniel Shao-Weng , Patel, Jyoti D. , Yang, Luxi , Kherani, Jennifer , Wirth, Lori J. , Robinson, Bruce , Solomon, Benjamin , Kang, Hyunseok , Worden, Francis P. , Leboulleux, Sophie , Morris, John C., Owonikoko, Taofeek Kunle , Gautschi, Oliver , Cabanillas, Maria E.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 3594-3594

10.1200/jco.2020.38.15_suppl.3594 Get It

3594 Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in RET-mutant medullary thyroid cancer (MTC). Methods: Patients with RET-mutant MTC were enrolled to the Phase 1/2 LIBRETTO-001 trial (NCT03157128), a global, multicenter trial (16 countries, 89 sites). Following the Phase 1 dose escalation portion of the trial, patients received the recommended dose of 160 mg orally twice daily. Each cycle was 28 days. The primary endpoint was objective response rate (ORR) per RECIST 1.1. Secondary endpoints included duration of response (DoR) and safety. Per health authority agreement, the primary analysis set was defined as the first 55 consecutively enrolled patients previously treated with multikinase inhibitors cabozantinib and/or vandetanib. Patients naïve to cabozantinib and vandetanib treatment were analyzed separately. All analyses were based on a 16-Dec-2019 data cutoff date. Results: In the primary analysis set of prior cabozantinib and/or vandetanib-treated patients with MTC (n = 55), the ORR by investigator assessment was 62% (95% CI 47.7–74.6, n = 34/55) and the median DoR was not reached (95% CI 18.4 months–not estimable) despite a median follow-up of 14.8 months. In cabozantinib/vandetanib treatment-naïve patients (n = 88), the ORR by investigator assessment was 69% (95% CI 58.6–78.7, n = 61/88, including 2 responses pending confirmation). Of the 59 confirmed responding patients, with a median follow-up of 8 months, responses were ongoing for 57 responders at the time of the analysis. In the safety analysis set consisting of all selpercatinib dosed patients (N = 702), the most common treatment-related adverse events (TRAEs) that occurred in ≥15% of patients were dry mouth (33.3%), increased AST (24.5%), increased ALT (23.8%), hypertension (23.2%), diarrhea (19.7%), and fatigue (16.8%). Only 2% (14 of 702) of patients discontinued selpercatinib for TRAEs. Conclusions: Selpercatinib use was associated with marked and durable antitumor activity in prior cabozantinib and/or vandetanib-treated patients and in cabozantinib/vandetanib-naïve patients with RET-mutant MTC, with the majority of responses ongoing in both cohorts. Selpercatinib was well tolerated. Efficacy data assessed by independent review committee based on the 16-Dec-2019 data cutoff date will be presented. Clinical trial information: NCT03157128 .
Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk
Zhu, Jingjing , Shu, Xiao-Ou , Bao, Jiandong , Milne, Roger L. , Du, Mengmeng , Goodman, Phyllis J. , Li, Donghui , Bracci, Paige M. , Gallinger, Steven , Arslan, Alan A. , Scélo, Ghislaine , Visvanathan, Kala , Haiman, Christopher A. , Petersen, Gloria M. , Wu, Lang , Shu, Xiao-Ou , Bao, Jiandong , Milne, Roger L , Malats, Nuria , Duell, Eric J , Li, Donghui , Katzke, Verena , Van Den Eeden, Stephen K , Arslan, Alan A , Canzian, Federico , Yu, Herbert , Klein, Alison P , Visvanathan, Kala , Guo, Xingyi , Liu, Duo, Giles, Graham G. , Wu, Chong , White, Emily , Risch, Harvey A. , Malats, Núria , Duell, Eric J. , Neale, Rachel Ε. , Canzian, Federico , Kooperberg, Charles , Freeman, Laura E. Beane , Marchand, Loı̈c Le , Yu, Kai , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Cai, Qiuyin , Long, Jirong , Zheng, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 21, 2020 | Volume: 29 | Issue: 7 | Pages: 1501-1508

10.1158/1055-9965.epi-20-0091 | PMID 32439797 Get It

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with few known risk factors and biomarkers. Several blood protein biomarkers have been linked to PDAC in previous studies, but these studies have assessed only a limited number of biomarkers, usually in small samples. In this study, we evaluated associations of circulating protein levels and PDAC risk using genetic instruments. Methods: To identify novel circulating protein biomarkers of PDAC, we studied 8,280 cases and 6,728 controls of European descent from the Pancreatic Cancer Cohort Consortium and the Pancreatic Cancer Case-Control Consortium, using genetic instruments of protein quantitative trait loci. Results: We observed associations between predicted concentrations of 38 proteins and PDAC risk at an FDR of < 0.05, including 23 of those proteins that showed an association even after Bonferroni correction. These include the protein encoded by ABO, which has been implicated as a potential target gene of PDAC risk variant. Eight of the identified proteins (LMA2L, TM11D, IP-10, ADH1B, STOM, TENC1, DOCK9, and CRBB2) were associated with PDAC risk after adjusting for previously reported PDAC risk variants (OR ranged from 0.79 to 1.52). Pathway enrichment analysis showed that the encoding genes for implicated proteins were significantly enriched in cancer-related pathways, such as STAT3 and IL15 production. Conclusions: We identified 38 candidates of protein biomarkers for PDAC risk. Impact: This study identifies novel protein biomarker candidates for PDAC, which if validated by additional studies, may contribute to the etiologic understanding of PDAC development.
cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading
Louis, David N. , Wesseling, Pieter , Aldape, Kenneth , Capper, David , Cree, Ian A. , Figarella‐Branger, Dominique , Fouladi, Maryam, Haberler, Christine , Hawkins, Cynthia , Komori, Takashi, Ng, Ho‐Keung , Orr, Brent A. , Paulus, Werner, Pietsch, Torsten , Reifenberger, Guido , Rosenblum, Marc, Rous, Brian , Sahm, Felix , Sarkar, Chitra , Solomon, David A. , Tabori, Uri , Bent, Martin J. van den , Deimling, Andreas von , Weller, Michael , White, Valerie A. , Ellison, David W. , Figarella-Branger, Dominique , Pietsch, Torsten , Sarkar, Chitra , Solomon, David A , Weller, Michael , van den Bent, Martin J , Orr, Brent A , Wesseling, Pieter , von Deimling, Andreas , Tabori, Uri , Sahm, Felix , Capper, David , Brat, Daniel J. , Eberhart, Charles G. , Fouladi, Maryam , Fuller, Gregory N. , Giannini, Caterina , Kros, Johan M. , Park, Sung-Hye , Perry, Arie , Rosenblum, Marc

Mayo Clinic

Brain Pathology | April 20, 2020 | Volume: 30 | Issue: 4 | Pages: 844-856

10.1111/bpa.12832 | PMID 32307792 Get It

Abstract cIMPACT‐NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to evaluate and make practical recommendations on recent advances in the field of CNS tumor classification, particularly in light of the rapid progress in molecular insights into these neoplasms. For Round 2 of its deliberations, cIMPACT‐NOW Working Committee 3 was reconstituted and convened in Utrecht, The Netherlands, for a meeting designed to review putative new CNS tumor types in advance of any future World Health Organization meeting on CNS tumor classification. In preparatory activities for the meeting and at the actual meeting, a list of possible entities was assembled and each type and subtype debated. Working Committee 3 recommended that a substantial number of newly recognized types and subtypes should be considered for inclusion in future CNS tumor classifications. In addition, the group endorsed a number of principles—relating to classification categories, approaches to classification, nomenclature, and grading—that the group hopes will also inform the future classification of CNS neoplasms.
Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria
Solomon, Andrew , Pettigrew, Roman, Chahin, Salim , Krieger, Stephen, Weinshenker, Brian G. , Weinshenker, Brian G , Naismith, Robert T.

Mayo Clinic

Multiple Sclerosis Journal | March 12, 2020 | Volume: 27 | Issue: 2 | Pages: 250-258

10.1177/1352458520910496 | PMID 32162581 Get It

Objective: To assess comprehension and application of the McDonald criteria. Background: Studies suggest that knowledge gaps for specific core elements of the McDonald criteria may contribute to multiple sclerosis (MS) misdiagnosis. Methods: Neurology residents (NR) and multiple sclerosis specialists (MSS) in North America completed a web-based survey. Results: A total of 160 participants were included: 72 NR and 88 MSS. Syndromes incorrectly identified as typical of MS included: complete transverse myelopathy (35% NR and 15% MSS), intractable vomiting/nausea/hiccoughs (20% NR and 5% MSS), and bilateral optic neuritis/unilateral optic neuritis with poor visual recovery (17% NR and 10% MSS). Periventricular magnetic resonance imaging (MRI) lesions were correctly identified by 39% NR and 52% MSS, and juxtacortical lesions were correctly identified by 28% NR and 53% MSS. The correct definition of “periventricular” was chosen by 38% NR and 61% MSS, and that of “juxtacortical” was chosen by 19% NR and 54% MSS. Regions incorrectly identified for MRI dissemination in space fulfillment included the optic nerve (31% NR and 26% MSS) and the subcortical white matter (11% NR and 18% MSS). The majority of participants assessed previous non-specific neurological symptoms without objective evidence of a central nervous system (CNS) lesion as sufficient for clinical dissemination in time. Conclusion: The McDonald criteria are often misunderstood and misapplied. Concerted educational efforts may prevent MS misdiagnosis.
A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition.
Northfelt, Donald W. , Hamburg, Solomon I. , Seetharam, ­Mahesh , Curtis, Kelly K., Crowell, Brynne, Vocila, Linda, Fredlund, Paul, Gilbert, M. Jean , Mast, Catherine Patricia, Semple, Sean C., Judge, Adam D., MacLachlan, Ian , Ramanathan, Ramesh K., Borad, Mitesh J. , Lee, Peter P.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: TPS2621-TPS2621

10.1200/jco.2013.31.15_suppl.tps2621 Get It

TPS2621 Background: TKM-080301 is a lipid nanoparticle formulation of a small interfering RNA (siRNA) directed against PLK1, a serine/threonine kinase that regulates multiple critical aspects of cell cycle progression and mitosis. Anti-tumor activity, RNA interference and pharmacodynamic effects of PLK1 inhibition have been conclusively demonstrated in preclinical models. Demonstration of pharmacodynamic effects of PLK1 inhibition in patient biopsy samples is an exploratory objective of this first-in-human study. Methods: TKME080301 is being evaluated in an open-label, non-randomized, dose-escalation study in patients with advanced solid tumors or lymphoma. Sequential cohorts of 3 to 6 patients receive TKME080301 as a 30-minute intravenous infusion on Days 1, 8 and 15 of a 28-day cycle. Treatment can continue until disease progression, based on overall clinical benefit. Tumor response is determined according to RECIST criteria. Primary study objectives include determination of safety, maximum tolerated dose and dose limiting toxicities. Secondary objectives include characterization of pharmacokinetics and the preliminary assessment of anti-tumor activity. Five cohorts have been enrolled and a tentative Phase 2 dose has been identified. An expansion cohort of 10 patients began enrolling in February, 2013. The focus of the expansion cohort will be to collect additional safety and pharmacokinetic data at the tentative Phase 2 dose, as well as pharmacodynamic data from mandatory biopsy samples. Pre- and post-dose biopsy samples will be evaluated for potential evidence of PLK1 inhibition using 5’ RACE (rapid amplification of cDNA ends) polymerase chain reaction (to identify the predicted PLK1 mRNA cleavage product), histology (to assess for the presence of aberrant mitotic figures) and immunohistochemistry. An update on enrollment and pharmacodynamic evaluations will be presented. Clinical trial information: NCT01262235.
Overall and cancer-specific survival of breast, colon, and lung cancer in patients with and without chronic lymphocytic leukemia: A SEER population-based study of over 1 million patients.
Solomon, Benjamin , Brewer, Jerry D., Rabe, Kari G. , Slager, Susan L. , Cerhan, James R. , Shanafelt, Tait D.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: 6571-6571

10.1200/jco.2012.30.15_suppl.6571 Get It

6571 Background: Chronic lymphocytic leukemia (CLL) is associated with an increased risk of developing second cancers. However, it is unknown whether CLL alters the natural history of these cancers once they occur. Methods: All patients with breast (n=583,838), colon (n=412,932), prostate (n=632,922), lung (n=489,290), kidney (n=95,902), pancreas (n=82,121) and ovarian (n=61,958) cancer reported to the Surveillance, Epidemiology, and End Results (SEER) Program from 1990 to 2007 were identified. Overall survival (OS; death due to any cause) and cancer-specific survival (death due to cancer site of interest) were examined, comparing patients with or without pre-existing CLL. Age- and sex-adjusted hazard ratios (HRs) were calculated. Results: OS for patients with pre-existing CLL was inferior for patients with breast (HR=1.61; p<0.001), colon (HR=1.65; p<0.001), kidney (HR=1.41; p<0.001), prostate (HR=1.75; p<0.001), and lung (HR=1.22; p<0.001) cancer after adjusting for age and sex. After excluding CLL-related deaths, OS remained shorter among patients with breast (p<0.001), colon (p<0.001), kidney (p=0.03), prostate (p<0.001), and lung (p<0.001) cancer. Cancer-specific survival was inferior for patients with breast (HR=1.29; p=0.03), colon (HR=1.75; p<0.001), and lung cancer (HR=1.17; p<0.001) who had pre-existing CLL after adjusting for age and sex. Conclusions: Several common cancers, including breast, colon, and lung, have inferior overall and cancer-specific survival when there is coexistent CLL. [Table: see text]